Sign in

    Laura Gris Trillo

    Research Analyst at Jefferies Financial Group

    Laura Gris Trillo is an Equity Research Analyst at Jefferies Financial Group specializing in European diversified financials, covering listed asset managers, wealth managers, and related financial sectors. She covers specific companies such as Ashmore Group and participates in the analysis of 34 stocks across the sector, with a recent buy recommendation on Ashmore reflecting her active research focus. Since joining Jefferies in August 2021, Laura Gris Trillo has contributed to high-profile research reports alongside her team, leveraging data-driven frameworks and expert calls to shape institutional investor perspectives. Her track record includes a 40% success rate with a TipRanks ranking of 1.09-stars, and her role is supported by professional registration as a regulated analyst with credentials in specialty and other finance segments.

    Laura Gris Trillo's questions to NEOGENOMICS (NEO) leadership

    Laura Gris Trillo's questions to NEOGENOMICS (NEO) leadership • Q2 2025

    Question

    Laura Gris Trillo from Jefferies Financial Group questioned the drivers behind the 23% NGS growth, asking to distinguish between test mix shift and true market expansion, and to comment on its sustainability.

    Answer

    President & COO Warren Stone clarified that the majority of the 23% NGS growth is driven by true market expansion and share gains from their dedicated oncology sales specialist team. While there is a positive mix benefit from the higher AUP of NGS tests, he emphasized that the volume growth is significantly outpacing the market. He expects the launch of PANTRACER Liquid to further accelerate this trend.

    Ask Fintool Equity Research AI

    Laura Gris Trillo's questions to NEOGENOMICS (NEO) leadership • Q2 2025

    Question

    Laura Gris Trillo of Jefferies Financial Group, on for Tycho Peterson, asked for a breakdown of the 23% NGS growth, questioning how much was driven by market expansion versus test mix, and its sustainability.

    Answer

    President & COO Warren Stone clarified that the majority of the NGS growth stems from true market expansion and share gains, driven by the company's specialized oncology sales force. He expressed confidence that this growth cadence is sustainable and will be further supported by the launch of PANTRACER Liquid.

    Ask Fintool Equity Research AI